[go: up one dir, main page]

DK1641434T3 - Farmaceutiske formuleringer til intranasal indgivelse af protein indeholdende chitosan eller et derivat deraf - Google Patents

Farmaceutiske formuleringer til intranasal indgivelse af protein indeholdende chitosan eller et derivat deraf

Info

Publication number
DK1641434T3
DK1641434T3 DK04743222T DK04743222T DK1641434T3 DK 1641434 T3 DK1641434 T3 DK 1641434T3 DK 04743222 T DK04743222 T DK 04743222T DK 04743222 T DK04743222 T DK 04743222T DK 1641434 T3 DK1641434 T3 DK 1641434T3
Authority
DK
Denmark
Prior art keywords
derivative
pharmaceutical formulations
protein containing
intranasal administration
containing chitosan
Prior art date
Application number
DK04743222T
Other languages
Danish (da)
English (en)
Inventor
Ann Margaret Dyer
Peter James Watts
Yu-Hui Cheng
Alan Smith
Original Assignee
Archimedes Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archimedes Dev Ltd filed Critical Archimedes Dev Ltd
Application granted granted Critical
Publication of DK1641434T3 publication Critical patent/DK1641434T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK04743222T 2003-07-04 2004-07-02 Farmaceutiske formuleringer til intranasal indgivelse af protein indeholdende chitosan eller et derivat deraf DK1641434T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0315632.0A GB0315632D0 (en) 2003-07-04 2003-07-04 Pharmaceutical formulations
PCT/GB2004/002876 WO2005004838A1 (en) 2003-07-04 2004-07-02 Pharmaceutical formulations for intranasal administration of protein comprising a chitosan or a derivative thereof

Publications (1)

Publication Number Publication Date
DK1641434T3 true DK1641434T3 (da) 2009-04-06

Family

ID=27741549

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04743222T DK1641434T3 (da) 2003-07-04 2004-07-02 Farmaceutiske formuleringer til intranasal indgivelse af protein indeholdende chitosan eller et derivat deraf

Country Status (14)

Country Link
US (2) US7662403B2 (pl)
EP (1) EP1641434B1 (pl)
AT (1) ATE417599T1 (pl)
AU (1) AU2004255515B2 (pl)
CA (1) CA2531239C (pl)
DE (1) DE602004018496D1 (pl)
DK (1) DK1641434T3 (pl)
ES (1) ES2319995T3 (pl)
GB (1) GB0315632D0 (pl)
NZ (1) NZ544718A (pl)
PL (1) PL1641434T3 (pl)
PT (1) PT1641434E (pl)
WO (1) WO2005004838A1 (pl)
ZA (1) ZA200600027B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0315632D0 (en) 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
US20090136505A1 (en) * 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
GB2438834A (en) * 2006-06-08 2007-12-12 Optinose As Intranasal protein administration
EP2043603A4 (en) * 2006-07-11 2010-10-27 Arubor Corp PREVENTION AND THERAPY OF RHINOSINUSITIS WITH PROINFLAMMATORY CYTOKINHERMERS
US20080182819A1 (en) * 2007-01-29 2008-07-31 Act Iii Licensing, Llc Chitosan compositions and methods for using chitosan compositions in the treatment of health disorders
GB0812742D0 (en) 2008-07-11 2008-08-20 Critical Pharmaceuticals Ltd Process
US8399635B2 (en) 2008-11-12 2013-03-19 Synedgen, Inc. Chitosan derivatives to treat animals or optimize animal health
US20140294977A1 (en) * 2011-11-23 2014-10-02 Durect Corporation Radiation-Sterilized Biodegradable Drug Delivery Composition
GB201319437D0 (en) * 2013-11-04 2013-12-18 Nanomerics Ltd Delivery of drugs
CN105764491A (zh) 2013-12-09 2016-07-13 度瑞公司 药物活性剂复合物、聚合物复合物，以及包括其的组合物和方法
SMT202500321T1 (it) * 2015-02-01 2025-11-10 Quetzal Therapeutics Llc Composizioni liofilizzate ad area superficiale elevata comprendenti arsenico per la somministrazione orale a pazienti
CN112601541B (zh) * 2018-06-22 2024-12-27 比欧拉利克斯有限公司 口服给药的生物聚合物制剂

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5690954A (en) * 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
GB8904370D0 (en) 1989-02-25 1989-04-12 Cosmas Damian Ltd Liquid delivery compositions
JPH07118170A (ja) * 1993-10-19 1995-05-09 Dot:Kk 経鼻吸収薬物用キャリヤ、生理活性ペプチド組成物およびその製造法
US20010053359A1 (en) * 1994-07-26 2001-12-20 Peter Watts Drug delivery composition for the nasal administration of antiviral agents
GB9416884D0 (en) 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
GB9419979D0 (en) 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
SE9403905D0 (sv) * 1994-11-14 1994-11-14 Astra Ab New formulations
GB9522351D0 (en) 1995-11-01 1996-01-03 Medeva Holdings Bv Vaccine compositions
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
ATE247456T1 (de) 1996-02-27 2003-09-15 Teijin Ltd Puderförmige zusammensetzung zur nasalen anwendung
US5912014A (en) * 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
DE69712110T2 (de) 1996-07-10 2002-12-12 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Ltd., Nottingham Zusammensetzungen zur einführung von genen in epithelzellen
GB9700624D0 (en) * 1997-01-14 1997-03-05 Danbiosyst Uk Drug delivery composition
GB9707934D0 (en) 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
GB9713980D0 (en) 1997-07-03 1997-09-10 Danbiosyst Uk New conjugates
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
NZ509710A (en) * 1998-07-08 2003-10-31 Kirin Amgen Inc Powdery preparation for mucosal administration containing polymeric medicine and a high molecular drug
SE9803239D0 (sv) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
GB9924797D0 (en) 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
US20020013331A1 (en) 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
KR20080053423A (ko) 2000-07-31 2008-06-12 니코메드 댄마크 에이에스 코 투여용 펜타닐 조성물
AU2002346424A1 (en) * 2001-11-19 2003-06-10 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
GB0315632D0 (en) 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations

Also Published As

Publication number Publication date
WO2005004838A1 (en) 2005-01-20
ES2319995T3 (es) 2009-05-18
AU2004255515A2 (en) 2005-01-20
NZ544718A (en) 2009-06-26
CA2531239A1 (en) 2005-01-20
AU2004255515A1 (en) 2005-01-20
GB0315632D0 (en) 2003-08-13
WO2005004838A8 (en) 2005-03-17
DE602004018496D1 (de) 2009-01-29
CA2531239C (en) 2011-05-24
PT1641434E (pt) 2009-03-19
ZA200600027B (en) 2009-08-26
EP1641434B1 (en) 2008-12-17
US7662403B2 (en) 2010-02-16
US8481070B2 (en) 2013-07-09
PL1641434T3 (pl) 2009-08-31
EP1641434A1 (en) 2006-04-05
US20100021553A1 (en) 2010-01-28
AU2004255515B2 (en) 2009-04-30
US20060120973A1 (en) 2006-06-08
ATE417599T1 (de) 2009-01-15

Similar Documents

Publication Publication Date Title
DK1641434T3 (da) Farmaceutiske formuleringer til intranasal indgivelse af protein indeholdende chitosan eller et derivat deraf
CY1108875T1 (el) Βλεννοπροσφυτικα σκευασματα που περιεχουν ξυλογλυκανη και ειναι χρησιμα σε ιατρικες συσκευες και σε φαρμακευτικα σκευασματα
DK1389137T3 (da) Sammensætninger til lungelægemiddellevering af protein
CY1105120T1 (el) Η αντιμετωπιση αναπνευστικων νοσων
FR11C0017I2 (fr) Utilisation de spinosad ou d'une formulation comprennant spinosad
AU2003295614A1 (en) Delivery of pharmaceutical agents via the human insulin receptor
EE05089B1 (et) Amiidasendatud imidasokinoliinid ja neid sisaldavad farmatseutilised preparaadid
DK1066044T3 (da) Dextranformuleringer til behandling af inflammatoriske ledsygdomme
WO2008021088A3 (en) Salicylanilides enhance oral delivery of therapeutic peptides
EE05074B1 (et) Sulfoonamiid- ja sulfamiidasendatud imidasokinoliinid, nende kasutamine raviks ja neid sisaldavad farmatseutilised preparaadid
ITMI20020399A0 (it) Composizioni dietetiche e/o farmaceutiche per uso umano e/o animale abase di preparati microbici probiotici
DE69528057D1 (de) Tocopherolzusammensetzungen zur Abgabe von biologisch aktiven Substanzen
DK0749317T3 (da) Terapeutiske anvendelser af dimerprodukter af baktericidt/permeabilitetsforøgende protein
DE602004019405D1 (de) Pharmazeutische zubereitungen
DE50005529D1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
DK1392254T3 (da) Micelle-lægemiddelindgivelsessystem for hydrofobe lægemidler
BRPI0415557A (pt) formulação contendo ingrediente ativo farmacêutico com revestimento
WO2003079993A3 (en) hGH (HUMAN GROWTH HORMONE) FORMULATIONS FOR PULMONARY ADMINISTRATION
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
ATE240717T1 (de) Wässrige formulierung zur nasalen verabreichung
IL179012A (en) A drug containing cetirizine for the treatment of nasal inflammation, a process for its preparation and use
ATE464878T1 (de) Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl
EP1501497A4 (en) CATECHIN MULTIMES THAN THERAPEUTIC DRUGS SUBSTITUTES
BR0206960A (pt) Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose
WO2003102014A3 (en) Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b